Phase I/II study of postoperative adjuvant therapy with Gemcitabine plus peptide vaccine for pancreatic cancer.

Phase I/II study of postoperative adjuvant therapy with Gemcitabine plus peptide vaccine for pancreatic cancer. - Phase I/II study of postoperative adjuvant therapy with Gemcitabine plus peptide vaccine for pancreatic cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004332

Enrollment

Registered

2010-10-06

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Patients will be treated with Gemcitabine within 10 weeks after curative operation and vaccinated biweekly for 12 times. On each vaccination day, VEGFR1 and VEGFR2 peptide (1mg) are mixed with Montan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.HLA-A2402 positive pancreatic cancer patients who received the curative operation 2.Age between 20 to 80 3.No severe organ function impairment 4.Written informed consent of the patient 5.Performance Status 0-2

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation 2.Decision of unsuitableness by principal investigatior 3.Patient with severe underlying disease 4.Patient with severe allergy disease

Design outcomes

Primary

Measure	Time frame
Assessment of safety Postoperative progression free survival Postoperative overall survival	—

Countries

Japan

Contacts

Public ContactTakashi Hatori

Tokyo Women's Medical University Department of Gastroenterological Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026